Lung Cancer Mutation Consortium Protocol
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/3/2019 |
| Start Date: | September 2009 |
| End Date: | July 2019 |
The primary objective of this protocol is to determine the frequency of oncogenic mutations
in 1000 patients with advanced adenocarcinoma of the lung. The linked clinical and mutational
analyses will be used to determine the frequency of each mutation, its association with
clinical features and outcome, and its association with other mutations. As future
therapeutic protocols specific for these mutations are developed, patients may be notified of
their eligibility for these studies. Future translational studies may be used to: a) unravel
the complex biology of lung cancer; b) identify prognostic markers; c) define predictive
markers of response/resistance to new therapies; d) identify new targets. A secondary goal is
to establish a consortium of sites that have the capability of conducting multiple mutation
testing in a Clinical Laboratory Improvement Amendments (CLIA) certified lab.
in 1000 patients with advanced adenocarcinoma of the lung. The linked clinical and mutational
analyses will be used to determine the frequency of each mutation, its association with
clinical features and outcome, and its association with other mutations. As future
therapeutic protocols specific for these mutations are developed, patients may be notified of
their eligibility for these studies. Future translational studies may be used to: a) unravel
the complex biology of lung cancer; b) identify prognostic markers; c) define predictive
markers of response/resistance to new therapies; d) identify new targets. A secondary goal is
to establish a consortium of sites that have the capability of conducting multiple mutation
testing in a Clinical Laboratory Improvement Amendments (CLIA) certified lab.
Inclusion Criteria:
1. Subjects (=> 18 years of age) who are undergoing further evaluation for the diagnosis
or treatment of advanced adenocarcinoma of the lung.
2. Diagnosed May 2012 or later
3. Oral and written informed consent.
Exclusion Criteria:
1. Lung cancer histologies other than adenocarcinoma
2. Lack of adequate tissue.
We found this trial at
1
site
Aurora, Colorado 80045
Principal Investigator: Paul Bunn, M.D.
Phone: 303-724-4168
Click here to add this to my saved trials
